Fight for Sight response to the Spark Therapeutics price for Luxturna

4 January 2018
Source: Fight for sight

George McNamara, Director of Research, Policy and Innovation of Fight for Sight, the eye research charity, comments that: “Gene therapy is a novel technique which holds the potential to deliver new treatments for those living with sight loss. The approval of Luxturna in the US highlights the importance of ensuring that as more gene therapies come into effect here in

Read more Fight for Sight response to the Spark Therapeutics price for Luxturna

The Guardian: US drug firm offers cure for blindness – at $425,000 an eye. With comment from RP Fighting Blindness

4 January 2018

Spark Therapeutics says ‘responsible price’ for Luxturna gene therapy ensures access for patients with retinal defect. A drug whose inventors claim it can cure a rare form of blindness is to be one of the most expensive medicines ever sold at $850,000 (£630,000). Luxturna is injected directly into the eye to address the root cause of visual impairment by replacing

Read more The Guardian: US drug firm offers cure for blindness – at $425,000 an eye. With comment from RP Fighting Blindness

Gene therapy company submit an application to NICE for the world’s first ever treatment for an inherited eye disease

10 August 2017
Source: Fight for Sight

Spark Therapeutics, an American gene therapy company, has published potentially ground-breaking data from the first ever Phase 3 clinical trial for an inherited retinal disease (IRD). This is the first time any treatment for a genetic disease has reached this stage. Published in the Lancet in July, the results illustrate how a new gene therapy drug called voretigene neparvovec could

Read more Gene therapy company submit an application to NICE for the world’s first ever treatment for an inherited eye disease